Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce a transformational acquisition, with the company entering into a definitive agreement to acquire Antev, a U.S.-based clinical-stage biopharmaceutical firm. The acquisition positions Medicus Pharma to significantly expand its pipeline into high-impact therapeutic areas, particularly in urology and men’s health. Under the terms of the agreement, Antev shareholders may receive up to US$65 million in additional contingent consideration, depending on the successful achievement of future milestones, including FDA Phase 2 and New Drug Application (NDA) approvals, as outlined in the definitive agreement. Antev is currently developing Teverelix, a next-generation GnRH antagonist being advanced as a first-in-market therapeutic for two high-need indications: cardiovascular high-risk prostate cancer patients and men experiencing their first episode of acute urinary retention (AURr) due to benign prostatic hyperplasia (BPH), commonly referred to as enlarged prostate. In addition to its pipeline expansion, Medicus Pharma is reinforcing its executive leadership to support its rapidly scaling global operations. Dr. Bokhari announced the appointment of Andrew Smith as Chief Operating Officer, bringing experience from Aberdeen Asset Management to help guide the company’s growth across North America, the Middle East, and Southeast Asia. To further strengthen governance and regulatory engagement, the company has nominated former U.S. Congresswoman Cathy McMorris Rodgers—who previously chaired the House Energy and Commerce Committee—to join its board. Her expertise in healthcare policy and FDA relations is expected to be instrumental as Medicus navigates the next phase of clinical and regulatory milestones. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation